PMID- 32943930
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - Exosome-Reversed Chemoresistance to Cisplatin in Non-Small Lung Cancer Through 
      Transferring miR-613.
PG  - 7961-7972
LID - 10.2147/CMAR.S254310 [doi]
AB  - INTRODUCTION: Non-small lung cancer (NSCLC) is one of the most common malignant 
      tumors in the world. Chemoresistance is the main reason of adverse effects 
      leading to the death of patients; thus, it is important to discover the potential 
      target of chemotherapeutic resistance. METHODS: The expression of differentially 
      expressed miRNA was detected in BEAS-2B, A549 and A549/cisplatin (DDP) by 
      qRT-PCR. Transmission electron microscopy (TEM) and exosome biomarkers were used 
      to validate the extracted exosome. Cells incubated with miR-613 enriched exosomes 
      were used to detect the function of exo-miR-613 in vitro. Then, exo-miR-613 was 
      injected to mice treated with DDP to investigate the function role of exo-miR-613 
      in vivo. RESULTS: Comparing to BEAS-2B, the expression of miR-613 inA549 was 
      significantly reduced, which was more obvious in A549/DDP. After incubated with 
      exo-miR-613 and corresponding exo-negative control (NC), we found overexpression 
      of miR-613 remarkably increased the inhibition of cell proliferation induced by 
      cisplatin. Exo-miR-613 fused into cells to significantly enhance the inhibited 
      effect of DDP on the proliferation, migration and showed a promotion on cell 
      apoptosis and DNA damage. The in vivo study showed that exo-miR-613 significantly 
      inhibited the tumor growth, and promote the sensitivity to DDP, probably by 
      down-regulating the expressions of GJA1, TBP and EIF-4E in tumor cells and 
      tissues. CONCLUSION: Exo-miR-613 reversed chemoresistance to DDP in NSCLC cell to 
      involve in the process of tumor progression, and might be a potential therapeutic 
      strategy for NSCLC.
CI  - (c) 2020 Li et al.
FAU - Li, Delong
AU  - Li D
AD  - Department of Special Geriatrics, Shanxi Cancer Hospital, Taiyuan, Shanxi, 
      People's Republic of China.
FAU - Meng, Debin
AU  - Meng D
AD  - Department of Special Geriatrics, Shanxi Cancer Hospital, Taiyuan, Shanxi, 
      People's Republic of China.
AD  - Department of General Surgery, Shanxi Cancer Hospital, Taiyuan, Shanxi, People's 
      Republic of China.
FAU - Niu, Rungui
AU  - Niu R
AD  - Department of Special Geriatrics, Shanxi Cancer Hospital, Taiyuan, Shanxi, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7481302
OTO - NOTNLM
OT  - apoptosis
OT  - chemoresistance
OT  - cisplatin
OT  - exosome
OT  - miRNA
OT  - non-small cell lung cancer
COIS- The authors report no funding and no conflicts of interest for this work.
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:01
PMCR- 2020/09/03
CRDT- 2020/09/18 05:49
PHST- 2020/03/17 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/09/18 05:49 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:01 [medline]
PHST- 2020/09/03 00:00 [pmc-release]
AID - 254310 [pii]
AID - 10.2147/CMAR.S254310 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 Sep 3;12:7961-7972. doi: 10.2147/CMAR.S254310. eCollection 
      2020.